Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT04087200
Recruiting Observational

Protective Effect of Early High Dose stATins On Cardiovascular and Renal Events in Acute Coronary Syndrome

NCT04087200 · tracked via the Priya Life Science Italy tracker
Sponsor
Centro Cardiopatici Toscani
Phase
Observational
Started
2016-12-01
Last updated
2019-09-12

Condition(s) studied

Acute Coronary Syndrome

Study summary

Registration of all ACS patients (STEMI and NSTEMI) admitted to the cardiology ward and scheduled for early invasive strategy. The aim is to evaluate the protective effects of early (on admission) high-dose high-potency statin therapy on early and mid-term cardiac and renal events in this subset of patients.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Acute coronary syndrome (ST elevation and non ST elevation) * Early invasive strategy Exclusion Criteria: * contraindication to statin therapy * refusal of consent

Primary outcome measure(s)

  • Acute renal function changes — Within 72 hours after hospital admission
    Changes in creatinine and/or cystatine values
  • Inflammatory profile changes — up to 1 month
    Changes from baseline in CRP values
  • Lipid profile changes — up to 1 month
    Changes from baseline in cholesterol values
  • Platelet count — up to 1 month
    Changes from baseline in platelet count
  • Platelet volume — up to 1 month
    Changes from baseline in platelet volume
  • Platelet aggregation profile — up to 1 month
    Changes from baseline in platelet reactivity (Verify Now)

Trial sites (1)

FacilityCityRegionStatus
Cardiology Division, Prato Hospital Prato Italy Recruiting

Other trials for the same condition

Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque Starting soon
Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry) Recruiting
AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS Active, not recruiting
LEADERS FREE II: BioFreedom™ Pivotal Study Active, not recruiting
Music Medicine in Coronary Interventional Cardiology Procedures Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04087200 on ClinicalTrials.gov ↗ ← All trials in Italy